Phase I/II Study of the Safety, Tolerability, Pharmacokinetics, and antiviral activity of Oral and Long-Acting Injectable Cabotegravir and Rilpivirine in Virologically Suppressed HIV-Infected
Baylor-Uganda is part of this ongoing multi-centre parallel, observational cohort study among HIV-uninfected pregnant adolescents and young women (aged 16-24) since March 2019.
This is a phase III randomised open-label clinical trial assessing virologic efficacy and safety of Dolutegravir-containing versus Efavirenz-containing ART regimens in HIV-1 infected pregnant women and their infants.
Compares safety and antiretroviral effect of current standard ART to once daily intergrase inhibitor (INSTI) administered with darunavir/ritonavir (DRV/r) in HIV-1 infected, virologically suppressed children. This ongoing two arm, phase […]
Evaluating the efficacy, safety and acceptability of weekends off DGT-based antiretroviral therapy (ART) and monthly long-acting injectable ART compared to daily DGT-based ART in virologically suppressed HIV-infected children and adolescents […]
A ViiV Health care funded randomised trial comparing efficacy and safety of dolutegravir (DTG)-based antiretroviral therapy (ART) versus standard of care (SOC) among HIV-infected children less than18years of age (≥3kg) […]
A multi-centre phase I/II proof-of-concept clinical trial exploring the effects of early intensive antiretroviral therapy (ART) on achieving HIV remission in neonates. Started in June 2015 at Baylor-Uganda’s Centre of […]
HPTN 084: Phase III Double Blind Safety and Efficacy Study of Long Acting Injectable Cabotegravir Compared to Daily Oral TDF/FTC for Pre-Exposure Prophylaxis in HIV-Uninfected Women Pictures of HPTN 084 […]